AM251, cannabinoids receptors ligand, improves recognition memory in rats

Pharmacological Reports

Volumn 63, Issue 3, 2011, Pages 670-679

  Bialuk, Izabela ^a   Winnicka, Maria M ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

AM251; Anxiety; Cannabinoids; Psychomotor activity; Rat; Recognition memory

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; LOCOMOTION; MALE; MAZE TEST; MEMORY CONSOLIDATION; MOTOR PERFORMANCE; NEUROPHARMACOLOGY; NONHUMAN; OPEN FIELD TEST; PSYCHOLOGIC ASSESSMENT; PSYCHOMOTOR ACTIVITY; RAT; RECOGNITION; SINGLE DRUG DOSE;

EID: 80051511864     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70578-3     Document Type: Article

References (50)

1. Alexander A, Smith PF, Rosengren RJ: Cannabinoids in the treatment of cancer. Cancer Lett, 2009, 285, 6-12.
2. Ameri A: The effects of cannabinoids on the brain. Prog Neurobiol, 1999, 58, 315-348.
3. Arevalo C, de Miguel R, Hernandez-Tristan R: Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav, 2001, 70, 123-131. (Pubitemid 32786974)
4. Bohme GA, Laville M, Ledent C, Parmentier M, Imperato A: Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors. Neuroscience, 2000, 95, 5-7.
5. Braszko JJ, Wisniewski K, Kupryszewski G, Witczuk B: Psychotropic effects of angiotensin II and III in rats: locomotor and exploratory vs cognitive behaviour. Behav Brain Res, 1987, 25, 195-203. (Pubitemid 17144142)
6. Brown AJ: Novel cannabinoid receptors. Br J Pharmacol, 2007, 152, 567-575.
7. Brusco A, Tagliaferro PA, Saez T, Onaivi ES: Ultrastructural localization of neuronal brain CB2 cannabinoid receptors. Ann NY Acad Sci, 2008, 1139, 450-457.
8. Budzyńska B, Kruk M, Biała G: Effects of the cannabinoid CB1 receptor antagonist AM 251 on the reinstatement of nicotine-conditioned place preference by drug priming in rats. Pharmacol Rep, 2009, 61, 304-310.
9. Castellano C, Rossi-Arnaud C, Cestari V, Costanzi M: Cannabinoids and memory: animal studies. Curr Drug Targets CNS Neurol Disord, 2003, 2, 389-402.
10. Chaperon F, Thiebot MH: Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol, 1999, 13, 243-281. (Pubitemid 30265251)
11. Cosenza M, Gifford AN, Gatley SJ, Pyatt B, Liu Q, Makriyannis A, Volkow ND: Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse, 2000, 38, 477-482.
12. Dawson RG, McGaugh JL: Modification of memory storage processes. Behav Sci, 1971, 16, 45-63.
13. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992, 258, 1946-1949. (Pubitemid 23026736)
14. Ennaceur A, Delacour J: A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res, 1988, 31, 47-59.
15. Fattore L, Fadda P, Spano MS, Pistis M, Fratta W: Neurobiological mechanisms of cannabinoid addiction. Mol Cell Endocrinol, 2008, 286, S97-S107.
16. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol, 1996, 307, 331-338.
17. Godlewski G, Offertaler L, Wagner JA, Kunos G: Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat, 2009, 89, 105-111.
18. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR: Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res, 2006, 1071, 10-23. (Pubitemid 43255471)
19. Hampson RE, Deadwyler SA: Role of cannabinoid receptors in memory storage. Neurobiol Dis, 1998, 5, 474-482. (Pubitemid 29075846)
20. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC et al.: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev, 2002, 54, 161-202. (Pubitemid 34575709)
21. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ: Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology, 2004, 47, Suppl 1, 345-358. (Pubitemid 39298276)
22. 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav, 2002, 73, 911-919.
23. Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME: Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem, 2009, 284, 29817-29827.
24. Kogan N, Mechoulam R: Cannabinoids in health and disease. Dialogues in clinical neuroscience, 2007, 9, 413-430.
25. Kosiorek P, Hryniewicz A, Bialuk I, Zawadzka A, Winnicka MM: Cannabinoids alter recognition memory in rats. Pol J Pharmacol, 2003, 55, 903-910.
26. Lichtman AH: SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur J Pharmacol, 2000, 404, 175-179.
27. Lichtman AH, Dimen KR, Martin BR: Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl), 1995, 119, 282-290.
28. Maccarrone M, Valverde O, Barbaccia ML, Castane A, Maldonado R, Ledent C, Parmentier M, Finazzi-Agrò A: Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur J Neurosci, 2002, 15, 1178-1186. (Pubitemid 35463618)
29. 9-Tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance. Life Sci, 1998, 62, 2431-2439.
30. 9- tetrahydrocannabinol or anandamide. Psychopharmacology (Berl), 1998, 140, 11-19.
31. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 1990, 346, 561-564.
32. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A et al.: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol, 1995, 50, 83-90.
33. New DC, Wong YH: BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates. FEBS Lett, 2003, 536, 157-160. (Pubitemid 36206424)
34. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, Myers L et al.: Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann NY Acad Sci, 2006, 1074, 514-536. (Pubitemid 44532857)
35. Pellow S, Chopin P, File SE, Briley M: Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods, 1985, 14, 149-167. (Pubitemid 16239568)
36. Pertwee RG: Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci, 2005, 76, 1307-1324.
37. Pertwee RG: Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol, 2009, 156, 397-411.
38. Pertwee RG, Ross RA: Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids, 2002, 66, 101-121. (Pubitemid 34743589)
39. Reibaud M, Obinu MC, Ledent C, Parmentier M, Bohme GA, Imperato A: Enhancement of memory in cannabinoid CB1 receptor knock-out mice. Eur J Pharmacol, 1999, 379, R1-R2. (Pubitemid 29492956)
40. Rodriguez de FF, Del A, I, Martin-Calderon JL, Gorriti MA, Navarro M: Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis, 1998, 5, 483-501.
41. Ross RA: The enigmatic pharmacology of GPR55. Trends Pharmacol Sci, 2009, 30, 156-163.
42. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T et al.: The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol, 2007, 152, 1092-1101. (Pubitemid 350166046)
43. Sanudo-Pena MC, Tsou K, Romero J, Mackie K, Walker JM: Role of the superior colliculus in the motor effects of cannabinoids and dopamine. Brain Res, 2000, 853, 207-214. (Pubitemid 30035220)
44. Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessegue B, Bonnin-Cabanne O, Le Fur G et al.: Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta, 1996, 1307, 132-136.
45. Steffens M, Szabo B, Klar M, Rominger A, Zentner J, Feuerstein TJ: Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex. Neuroscience, 2003, 120, 455-465. (Pubitemid 37288780)
46. Takahashi RN, Pamplona FA, Fernandes MS: The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze. Neurosci Lett, 2005, 380, 270-275. (Pubitemid 40616094)
47. Terranova JP, Storme JJ, Lafon N, Perio A, Rinaldi- Carmona M, Le FG, Soubrie P: Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl), 1996, 126, 165-172. (Pubitemid 26246767)
48. Wȩdzony K, Chocyk A: Cannabinoid CB1 receptors in rat medial prefrontal cortex are colocalized with calbindin- but not parvalbumin- and calretinin-positive GABA-ergic neurons. Pharmacol Rep, 2009, 61, 1000-1007.
49. Wilson RI, Nicoll RA: Endocannabinoid signaling in the brain. Science, 2002, 296, 678-682.
50. Wolff MC, Leander JD: SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task. Eur J Pharmacol, 2003, 477, 213-217. (Pubitemid 38366393)